Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Atrium Therapeutics, Inc.NASDAQ: RNA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow of $301.51M in Q1 FY2026

Q1 FY2026 financing cash flow was $301.51M.

Context

  • Financing cash flow amounted to 228.7% of revenue in FY2025.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$301.51M+1397.7% QoQ
Last fiscal yearDec 2025
$42.57M— YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
42.57M USD
Year-over-year change
—

Financing Cash Flow vs competitors

How RNA compares with its peers on the latest reported figures

No competitor Financing Cash Flow figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.